Knoll Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.7M | Hold |
2,328,602
| – | – | 10.93% | 1 |
|
|
2025
Q4 | $26.3M | Buy |
2,328,602
+1,433,333
| +160% | +$16.2M | 12.06% | 2 |
|
|
2025
Q3 | $13.4M | Hold |
895,269
| – | – | 7.2% | 2 |
|
|
2025
Q2 | $12.6M | Buy |
895,269
+64,390
| +8% | +$909K | 8.98% | 2 |
|
|
2025
Q1 | $20M | Buy |
830,879
+70,457
| +9% | +$1.69M | 12.99% | 2 |
|
|
2024
Q4 | $28.4M | Buy |
760,422
+50,000
| +7% | +$1.87M | 18.28% | 1 |
|
|
2024
Q3 | $35.5M | Hold |
710,422
| – | – | 16.45% | 2 |
|
|
2024
Q2 | $24.7M | Buy |
710,422
+220,000
| +45% | +$7.64M | 16.62% | 2 |
|
|
2024
Q1 | $26.8M | Hold |
490,422
| – | – | 16.69% | 2 |
|
|
2023
Q4 | $21M | Hold |
490,422
| – | – | 17.38% | 1 |
|
|
2023
Q3 | $12.8M | Buy |
490,422
+40,000
| +9% | +$1.04M | 13.24% | 3 |
|
|
2023
Q2 | $10.8M | Hold |
450,422
| – | – | 13.06% | 2 |
|
|
2023
Q1 | $6.15M | Hold |
450,422
| – | – | 9.48% | 2 |
|
|
2022
Q4 | $6.25M | Sell |
450,422
-450,422
| -50% | -$68.4M | 14.11% | 2 |
|
|
2022
Q3 | $136M | Hold |
900,844
| – | – | 79.57% | 1 |
|
|
2022
Q2 | $131M | Hold |
900,844
| – | – | 75% | 1 |
|
|
2022
Q1 | $107M | Buy |
900,844
+4,000
| +0.4% | +$499K | 67.04% | 1 |
|
|
2021
Q4 | $124M | Buy |
896,844
+40,000
| +5% | +$5.09M | 67.92% | 1 |
|
|
2021
Q3 | $119M | Hold |
856,844
| – | – | 59.36% | 1 |
|
|
2021
Q2 | $83.2M | Hold |
856,844
| – | – | 43.44% | 1 |
|
|
2021
Q1 | $58.6M | Sell |
856,844
-650
| -0.1% | -$52.6K | 38.16% | 1 |
|
|
2020
Q4 | $73.5M | Hold |
857,494
| – | – | 50.11% | 1 |
|
|
2020
Q3 | $55.7M | Hold |
857,494
| – | – | 45.68% | 1 |
|
|
2020
Q2 | $62.1M | Hold |
857,494
| – | – | 35.84% | 1 |
|
|
2020
Q1 | $29.2M | Hold |
857,494
| – | – | 27.41% | 1 |
|
|
2019
Q4 | $46.6M | Hold |
857,494
| – | – | 34.43% | 1 |
|
|
2019
Q3 | $35.8M | Buy |
857,494
+107,679
| +14% | +$4.55M | 32.74% | 1 |
|
|
2019
Q2 | $32.8M | Hold |
749,815
| – | – | 26.88% | 2 |
|
|
2019
Q1 | $38.6M | Hold |
749,815
| – | – | 29.33% | 1 |
|
|
2018
Q4 | $27.7M | Hold |
749,815
| – | – | 31.54% | 1 |
|
|
2018
Q3 | $27.9M | Hold |
749,815
| – | – | 23.6% | 3 |
|
|
2018
Q2 | $29.6M | Hold |
749,815
| – | – | 25.18% | 2 |
|
|
2018
Q1 | $19.3M | Sell |
749,815
-57,409
| -7% | -$1.72M | 19.83% | 3 |
|
|
2017
Q4 | $21.8M | Hold |
807,224
| – | – | 19.2% | 3 |
|
|
2017
Q3 | $30.1M | Hold |
807,224
| – | – | 25.78% | 2 |
|
|
2017
Q2 | $20.2M | Buy |
+807,224
| New | +$18.6M | 26.75% | 2 |
|
Knoll Capital Management's BHVN Position: Q1 2026 in Review
Knoll Capital Management held its Biohaven Pharmaceutical Holding Company Ltd. (BHVN) position steady in Q1 2026 at 2,328,602 shares worth $19.7M. The position accounts for 10.93% of the portfolio, ranked #1.
Knoll Capital Management first reported a position in BHVN in Q2 2017 and has held it in 36 quarters since. The position peaked at $136M in Q3 2022. 1 fund tracked by Wall St. Rank holds BHVN as of Q1 2026.
- Knoll Capital Management held 2,328,602 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $19.7M as of Q1 2026.
- Knoll Capital Management left its Biohaven Pharmaceutical Holding Company Ltd. share count unchanged in Q1 2026.
- Biohaven Pharmaceutical Holding Company Ltd. made up 10.93% of Knoll Capital Management's portfolio in Q1 2026, its #1 holding.
- Knoll Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and has held it in 36 quarters since.
- Knoll Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $136M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2026.
Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.